Celluris
Model CAR-T - Chimeric T Cell Antigen Receptor Therapy
FromCelluris
The chimeric T cell antigen receptor therapy, also known as CAR-T, is an immunotherapy that is innovating the treatment of hematological and solid tumors. This new technology is considered less aggressive than conventional treatments, since it focuses only on cancer cells, not attacking healthy cells.
Most popular related searches
T-cell
antigen receptor
T-cell receptor
T-cell therapy
solid tumor
cancer cell
cell therapy
CAR-T immunotherapy
car-t cell
hematologic
It is worth mentioning that the patient’s T-cells are modified according to the tumor the person is facing. Thus, the treatment is personalized, ensuring greater effectiveness.
Approved in 2017 in the United States and already available in Israel and Europe, this type of treatment is being tested in Brazil. Celluris is a pioneer in the country in research and development of CAR-T technology.